(MedPage Today) — A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations, a randomized trial showed. In… Source link : https://www.medpagetoday.com/meetingcoverage/sgo/114711 Author : Publish date : 2025-03-18 16:19:00 Copyright for syndicated content belongs to the linked Source.
The post Pembrolizumab-Olaparib Boosts PFS in Non-BRCA Ovarian Cancer first appeared on News Health.
Author : News Health
Publish date : 2025-03-18 16:19:00
Copyright for syndicated content belongs to the linked Source.